表紙
市場調査レポート

武田薬品工業 - 製品パイプライン分析

Takeda Pharmaceutical Company Limited - Product Pipeline Review - 2016

発行 Global Markets Direct 商品コード 251724
出版日 ページ情報 英文 266 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.18円で換算しております。
Back to Top
武田薬品工業 - 製品パイプライン分析 Takeda Pharmaceutical Company Limited - Product Pipeline Review - 2016
出版日: 2016年06月30日 ページ情報: 英文 266 Pages
概要

武田薬品工業は研究志向型の世界的な製薬企業で、日本では最大の製薬企業です。各種化学製品、ビタミンバルク、試薬、臨床診断用医薬品をはじめとする幅広い種類の製品を取り扱っています。

当レポートでは、武田薬品工業における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

目次

武田薬品工業 の基本情報

  • 武田薬品工業 の概要
  • 主要情報
  • 企業情報

武田薬品工業 :R&Dの概要

  • 主な治療範囲

武田薬品工業 :パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • 併用療法モダリティ
  • パートナー製品
  • アウトライセンス製品

武田薬品工業 :パイプライン製品の概況

  • 後期段階にあるパイプライン製品
  • 臨床段階にあるパイプライン製品
  • 初期段階にあるパイプライン製品

武田薬品工業 :薬剤プロファイル

  • (alogliptin benzoate + metformin hydrochloride)
  • (alogliptin benzoate + pioglitazone hydrochloride)
  • alogliptin benzoate
  • ceftaroline fosamil
  • glatiramer acetate
  • haemophilus influenzae serotype B vaccine
  • ramelteon
  • roflumilast
  • vedolizumab
  • (amlodipine besylate + azilsartan medoxomil + hydrochlorothiazide)
  • azilsartan medoxomil
  • febuxostat XR
  • immune globulin (human)
  • rasagiline mesylate
  • trebananib
  • vortioxetine hydrobromide
  • risedronate sodium
  • AM-4
  • DSM-265
  • MLN-1202
  • motesanib diphosphate
  • namilumab
  • relugolix
  • TAK-003
  • TAK-063
  • TAK-114
  • TAK-214
  • TAK-272
  • TAK-850
  • fulranumab
  • TAK-020
  • TAK-021
  • TAK-058
  • TAK-079
  • TAK-233
  • TAK-648
  • TAK-915
  • TAK-935
  • tedatioxetine
  • BTZO-15
  • BTZO-2
  • chikungunya vaccine
  • ELQ-300
  • influenza strain H5N1 vaccine
  • influenza vaccine
  • mapatumumab
  • modified vaccinia ankara vaccine
  • Monoclonal Antibody Conjugate for Cancer
  • Monoclonal Antibody Conjugated to Target c-Ret for Breast Cancer
  • respiratory syncytial virus vaccine
  • rotavirus vaccine
  • RUSKI-43
  • Small Molecule to Activate Glucokinase for Type 2 Diabetes
  • Small Molecule to Agonize Cannabinoid Receptor for Inflammatory Pain
  • Small Molecule to Agonize GPR52 for Psychiatry Disorders
  • Small Molecule to Antagonize Androgen Receptor for Prostate Cancer
  • Small Molecule to Antagonize Mineralocorticoid Receptor for Hypertension
  • Small Molecule to Antagonize Neurokinin-1 Receptor for Overactive Bladder
  • Small Molecule to Antagonize PDGFR and VEGFR-2 for Cancer
  • Small Molecule to Inhibit BTK for Rheumatoid Arthritis
  • Small Molecule to Inhibit Dopamine Transporter, Noradrenaline Transporter and Serotonin Transporter for Depression
  • Small Molecule to Inhibit FAAH for Pain
  • Small Molecule to Inhibit Farnesoid X Receptor for Dyslipidemia
  • Small Molecule to Inhibit Gamma Secretase for Alzheimer's Disease
  • Small Molecule to Inhibit HER2/EGFR for Cancer
  • Small Molecule to Inhibit MCHR1 for Obesity
  • Small Molecule to Inhibit Serotonin-Norepinephrine-Dopamine Reuptake for Depression
  • Small Molecules for Cognitive Impairment Associated with Schizophrenia
  • Small Molecules for Parkinson's Disease
  • Small Molecules for Visceral Leishmaniasis
  • Small Molecules to Agonize GPR119 for Type II Diabetes
  • Small Molecules to Antagonize c-Met and VEGFR2 for Cancer
  • Small Molecules to Inhibit Acetyl-CoA Carboxylase for Obesity
  • Small Molecules to Inhibit CENP-E for Cancer
  • Small Molecules to Inhibit DPP-IV for Type 2 Diabetes
  • Small Molecules to Inhibit Hedgehog Signaling for Medulloblastoma
  • Small Molecules to Inhibit PARP-1 for Cancer
  • Stem Cell Therapy for Muscular Dystrophy
  • T-1840383
  • T-3256336
  • TAK-075
  • TAK-480
  • TAK-632
  • TAK-792
  • Y-443
  • Antibodies for Undisclosed Indication
  • Drug to Inhibit PDE for Leishmaniasis and Trypanosomiasis
  • Small Molecule for Undisclosed Indication
  • Small Molecule to Inhibit Arginine Methyltrasferase for Cancer
  • Small Molecule to Inhibit FAK for Cancer
  • Small Molecule to Inhibit HDAC6 for Undisclosed Indication
  • Small Molecule to Inhibit HER2 and EGFR for Cancer
  • Small Molecule to Inhibit IAP for Cancer
  • Small Molecules for Malaria
  • Small Molecules for Tuberculosis
  • Small Molecules to Inhibit Apoptosis Signal-Regulating Kinase 1 for Undisclosed Indication
  • Small Molecules to Inhibit Mcl-1 and Bcl-xL for Cancer
  • Small Molecules to Inhibit MMP-13 for Osteoarthritis
  • Y-142

武田薬品工業 :パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

武田薬品工業 :最新のパイプライン情報

武田薬品工業 :開発休止中のプロジェクト

武田薬品工業 :開発が中止されたパイプライン製品

  • 開発が中止されたパイプライン製品のプロファイル

武田薬品工業 :企業理念

武田薬品工業 :本社と子会社の所在地

  • 本社
  • 支社および子会社

武田薬品工業 :主要な製造施設

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC08080CDB

Summary

Global Markets Direct's, 'Takeda Pharmaceutical Company Limited - Product Pipeline Review - 2016', provides an overview of the Takeda Pharmaceutical Company Limited's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Takeda Pharmaceutical Company Limited, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Takeda Pharmaceutical Company Limited
  • The report provides overview of Takeda Pharmaceutical Company Limited including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Takeda Pharmaceutical Company Limited's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Takeda Pharmaceutical Company Limited's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Takeda Pharmaceutical Company Limited's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Takeda Pharmaceutical Company Limited
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Takeda Pharmaceutical Company Limited's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Takeda Pharmaceutical Company Limited Snapshot
    • Takeda Pharmaceutical Company Limited Overview
    • Key Information
    • Key Facts
  • Takeda Pharmaceutical Company Limited - Research and Development Overview
    • Key Therapeutic Areas
  • Takeda Pharmaceutical Company Limited - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Partnered Products
    • Pipeline Products - Out-Licensed Products
  • Takeda Pharmaceutical Company Limited - Pipeline Products Glance
    • Takeda Pharmaceutical Company Limited - Late Stage Pipeline Products
      • Takeda Pharmaceutical Company Limited - Clinical Stage Pipeline Products
      • Takeda Pharmaceutical Company Limited - Early Stage Pipeline Products
  • Takeda Pharmaceutical Company Limited - Drug Profiles
    • (alogliptin benzoate + metformin hydrochloride)
    • (alogliptin benzoate + pioglitazone hydrochloride)
    • brentuximab vedotin
    • ceftaroline fosamil
    • ixazomib citrate
    • ramelteon
    • vedolizumab
    • roflumilast
    • (amlodipine besylate + azilsartan medoxomil + hydrochlorothiazide)
    • azilsartan medoxomil
    • febuxostat XR
    • immune globulin (human)
    • pioglitazone hydrochloride
    • rasagiline mesylate
    • relugolix
    • TAK-003
    • vortioxetine hydrobromide
    • AM-4
    • DSM-265
    • namilumab
    • TAK-063
    • TAK-214
    • TAK-272
    • TAK-850
    • J-591
    • TAK-020
    • TAK-021
    • TAK-058
    • TAK-071
    • TAK-079
    • TAK-653
    • TAK-792
    • TAK-828
    • TAK-831
    • TAK-915
    • TAK-935
    • trelagliptin succinate
    • (plague + small pox) vaccine
    • BTZO-2
    • chikungunya vaccine
    • ELQ-300
    • influenza [strain A/H5N1] vaccine
    • influenza [strains A/H1N1 + A/H3N2 + A/H5N1] (virus like particle) vaccine
    • mapatumumab
    • Monoclonal Antibody Conjugate to Target c-Ret for Breast Cancer
    • Monoclonal Antibody Conjugate to Target Guanylyl Cyclase C for Oncology
    • Monoclonal Antibody Conjugates for Oncology
    • respiratory syncytial virus (virus like particle) vaccine
    • Rotavirus (virus like particle) vaccine
    • Small Molecule 1 to Inhibit Dopamine Transporter, Noradrenaline Transporter and Serotonin Transporter for Depression
    • Small Molecule 2 to Inhibit Gamma Secretase for Alzheimer's Disease
    • Small Molecule to Activate Glucokinase for Type 2 Diabetes
    • Small Molecule to Agonize Cannabinoid Receptor for Inflammatory Pain
    • Small Molecule to Agonize GPR52 for Psychiatry Disorders
    • Small Molecule to Antagonize Androgen Receptor for Prostate Cancer
    • Small Molecule to Antagonize CRF1 for CNS Disorders
    • Small Molecule to Antagonize Farnesoid X Receptor for Dyslipidemia
    • Small Molecule to Antagonize MCHR1 for Obesity
    • Small Molecule to Antagonize Mineralocorticoid Receptor for Hypertension
    • Small Molecule to Antagonize PDGFR and VEGFR-2 for Oncology
    • Small Molecule to Inhibit Dopamine Transporter, Noradrenaline Transporter and Serotonin Transporter for Depression
    • Small Molecule to Inhibit FAAH for Pain
    • Small Molecule to Inhibit Gamma Secretase for Alzheimer's Disease
    • Small Molecule to Inhibit HER2/EGFR for Oncology
    • Small Molecule to Inhibit NET for Stress Urinary Incontinence
    • Small Molecule to Inhibit PKC-Theta
    • Small Molecules for Parkinson's Disease
    • Small Molecules for Visceral Leishmaniasis
    • Small Molecules to Agonize GPR119 for Type II Diabetes
    • Small Molecules to Inhibit Acetyl-CoA Carboxylase for Obesity
    • Small Molecules to Inhibit B-Raf for Oncology
    • Small Molecules to Inhibit CENP-E for Colon Cancer
    • Small Molecules to Inhibit DPP-IV for Type 2 Diabetes
    • Small Molecules to Inhibit Hedgehog Signaling for Medulloblastoma
    • Small Molecules to Inhibit MAP2 for Obesity
    • Small Molecules to Inhibit MGAT2 for Metabolic Disorders
    • Small Molecules to Inhibit MMP-13 for Osteoarthritis
    • Small Molecules to Inhibit PARP-1 for Colon Cancer
    • Small Molecules to Inhibit TYK2
    • Stem Cell Therapy for Muscular Dystrophy
    • T-1840383
    • T-3256336
    • TAK-041
    • TAK-480
    • TAK-632
    • Y-443
    • Small Molecule for Undisclosed Indication
    • Small Molecule to Inhibit Arginine Methyltrasferase for Oncology
    • Small Molecule to Inhibit HDAC6
    • Small molecules for Leishmaniasis and Trypanosomiasis
    • Small Molecules for Malaria
    • Small Molecules for Tuberculosis
    • Small Molecules to Inhibit Apoptosis Signal-Regulating Kinase 1
    • Small Molecules to Inhibit FAK for Oncology
    • Small Molecules to Inhibit HER2 and EGFR for Oncology
    • Small Molecules to Inhibit IAP for Oncology
    • Small Molecules to Inhibit Mcl-1 and Bcl-xL for Oncology
    • Y-142
  • Takeda Pharmaceutical Company Limited - Pipeline Analysis
    • Takeda Pharmaceutical Company Limited - Pipeline Products by Target
    • Takeda Pharmaceutical Company Limited - Pipeline Products by Route of Administration
    • Takeda Pharmaceutical Company Limited - Pipeline Products by Molecule Type
    • Takeda Pharmaceutical Company Limited - Pipeline Products by Mechanism of Action
  • Takeda Pharmaceutical Company Limited - Recent Pipeline Updates
  • Takeda Pharmaceutical Company Limited - Dormant Projects
  • Takeda Pharmaceutical Company Limited - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
  • Takeda Pharmaceutical Company Limited - Company Statement
  • Takeda Pharmaceutical Company Limited - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Takeda Pharmaceutical Company Limited, Key Information
  • Takeda Pharmaceutical Company Limited, Key Facts
  • Takeda Pharmaceutical Company Limited - Pipeline by Indication, 2016
  • Takeda Pharmaceutical Company Limited - Pipeline by Stage of Development, 2016
  • Takeda Pharmaceutical Company Limited - Monotherapy Products in Pipeline, 2016
  • Takeda Pharmaceutical Company Limited - Combination Treatment Modalities in Pipeline, 2016
  • Takeda Pharmaceutical Company Limited - Partnered Products in Pipeline, 2016
  • Takeda Pharmaceutical Company Limited - Partnered Products/ Combination Treatment Modalities, 2016
  • Takeda Pharmaceutical Company Limited - Out-Licensed Products in Pipeline, 2016
  • Takeda Pharmaceutical Company Limited - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • Takeda Pharmaceutical Company Limited - Pre-Registration, 2016
  • Takeda Pharmaceutical Company Limited - Filing rejected/Withdrawn, 2016
  • Takeda Pharmaceutical Company Limited - Phase III, 2016
  • Takeda Pharmaceutical Company Limited - Phase II, 2016
  • Takeda Pharmaceutical Company Limited - Phase I, 2016
  • Takeda Pharmaceutical Company Limited - Phase 0, 2016
  • Takeda Pharmaceutical Company Limited - IND/CTA Filed, 2016
  • Takeda Pharmaceutical Company Limited - Preclinical, 2016
  • Takeda Pharmaceutical Company Limited - Discovery, 2016
  • Takeda Pharmaceutical Company Limited - Pipeline by Target, 2016
  • Takeda Pharmaceutical Company Limited - Pipeline by Route of Administration, 2016
  • Takeda Pharmaceutical Company Limited - Pipeline by Molecule Type, 2016
  • Takeda Pharmaceutical Company Limited - Pipeline Products by Mechanism of Action, 2016
  • Takeda Pharmaceutical Company Limited - Recent Pipeline Updates, 2016
  • Takeda Pharmaceutical Company Limited - Dormant Developmental Projects,2016
  • Takeda Pharmaceutical Company Limited - Discontinued Pipeline Products, 2016
  • Takeda Pharmaceutical Company Limited, Other Locations
  • Takeda Pharmaceutical Company Limited, Subsidiaries

List of Figures

  • Takeda Pharmaceutical Company Limited - Pipeline by Top 10 Indication, 2016
  • Takeda Pharmaceutical Company Limited - Pipeline by Stage of Development, 2016
  • Takeda Pharmaceutical Company Limited - Monotherapy Products in Pipeline, 2016
  • Takeda Pharmaceutical Company Limited - Combination Treatment Modalities in Pipeline, 2016
  • Takeda Pharmaceutical Company Limited - Partnered Products in Pipeline, 2016
  • Takeda Pharmaceutical Company Limited - Out-Licensed Products in Pipeline, 2016
  • Takeda Pharmaceutical Company Limited - Pipeline by Top 10 Target, 2016
  • Takeda Pharmaceutical Company Limited - Pipeline by Route of Administration, 2016
  • Takeda Pharmaceutical Company Limited - Pipeline by Molecule Type, 2016
  • Takeda Pharmaceutical Company Limited - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top